SG11202105469YA - 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors - Google Patents
2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitorsInfo
- Publication number
- SG11202105469YA SG11202105469YA SG11202105469YA SG11202105469YA SG11202105469YA SG 11202105469Y A SG11202105469Y A SG 11202105469YA SG 11202105469Y A SG11202105469Y A SG 11202105469YA SG 11202105469Y A SG11202105469Y A SG 11202105469YA SG 11202105469Y A SG11202105469Y A SG 11202105469YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- methionine adenosyltransferase
- oxoquinazoline derivatives
- oxoquinazoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862777715P | 2018-12-10 | 2018-12-10 | |
US201962835853P | 2019-04-18 | 2019-04-18 | |
US201962883945P | 2019-08-07 | 2019-08-07 | |
PCT/US2019/065260 WO2020123395A1 (en) | 2018-12-10 | 2019-12-09 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105469YA true SG11202105469YA (en) | 2021-06-29 |
Family
ID=69138003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105469YA SG11202105469YA (en) | 2018-12-10 | 2019-12-09 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
Country Status (17)
Country | Link |
---|---|
US (4) | US20220106276A1 (en) |
EP (1) | EP3894396A1 (en) |
JP (1) | JP2022512156A (en) |
KR (1) | KR20210103498A (en) |
CN (1) | CN113166078A (en) |
AU (1) | AU2019395338A1 (en) |
BR (1) | BR112021010842A2 (en) |
CA (1) | CA3121236A1 (en) |
CL (1) | CL2021001508A1 (en) |
CO (1) | CO2021008895A2 (en) |
IL (1) | IL283743A (en) |
MA (1) | MA54452A (en) |
MX (1) | MX2021006841A (en) |
PH (1) | PH12021551274A1 (en) |
SG (1) | SG11202105469YA (en) |
TW (1) | TW202039487A (en) |
WO (1) | WO2020123395A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4165035A1 (en) * | 2020-06-10 | 2023-04-19 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
BR112022026105A2 (en) * | 2020-06-22 | 2023-01-17 | Hoffmann La Roche | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR THE TREATMENT OR PREVENTION OF PULMONARY ADENOCARCINOMA, USE OF COMPOUNDS AND INVENTION |
JP2023531021A (en) * | 2020-06-22 | 2023-07-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | amidopyrimidone derivative |
CN116406271A (en) * | 2020-07-14 | 2023-07-07 | 江苏先声药业有限公司 | Bicyclic compounds |
WO2022063128A1 (en) * | 2020-09-24 | 2022-03-31 | 上海凌达生物医药有限公司 | Aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and use thereof |
US20230072276A1 (en) * | 2020-12-15 | 2023-03-09 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
TW202227443A (en) | 2020-12-31 | 2022-07-16 | 中國商江蘇先聲藥業有限公司 | Tricyclic compound and use thereof |
WO2022206730A1 (en) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | Pyrimidopyrazine compound and use thereof |
WO2022222911A1 (en) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | Pyrimidone compound and use thereof |
WO2022228515A1 (en) * | 2021-04-30 | 2022-11-03 | 赛诺哈勃药业(成都)有限公司 | Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof |
KR20240019172A (en) * | 2021-06-02 | 2024-02-14 | 아이디어야 바이오사이언시스 인코포레이티드 | Combination therapy involving a MAT2A inhibitor and a type II PRMT inhibitor |
WO2022256808A1 (en) * | 2021-06-02 | 2022-12-08 | Ideaya Biosciences Inc. | Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor |
CN117412967A (en) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | Methionine adenosine transferase 2A inhibitors |
TW202327600A (en) * | 2021-10-20 | 2023-07-16 | 香港商英科智能有限公司 | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof |
WO2023083210A1 (en) * | 2021-11-09 | 2023-05-19 | 上海海雁医药科技有限公司 | Substituted naphthyridinone derivative, and pharmaceutical composition thereof and use thereof |
WO2023086934A1 (en) * | 2021-11-12 | 2023-05-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
WO2023116696A1 (en) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | Methionine adenosyltransferase 2a heterocyclic inhibitor |
WO2023143356A1 (en) * | 2022-01-26 | 2023-08-03 | 勤浩医药(苏州)有限公司 | Methionine adenosyltransferase 2a inhibitor for treating mtap deletion-type cancer |
WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2024080788A1 (en) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | Novel tricyclic derivative compound and uses thereof |
CN117777134A (en) * | 2022-12-19 | 2024-03-29 | 艾立康药业股份有限公司 | Polycyclic compounds as MAT2A inhibitors |
CN116283800B (en) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | Oxo quinazoline compound and application thereof |
CN116478172B (en) * | 2023-06-20 | 2023-09-05 | 英矽智能科技(上海)有限公司 | Pyrrolo [3,2-d ] pyrimidine compound and application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5761758B2 (en) | 1974-01-11 | 1982-12-25 | Hisamitsu Pharmaceutical Co | |
EP0759454B1 (en) | 1994-05-11 | 2002-03-06 | Asahi Kasei Kabushiki Kaisha | para-ORIENTED AROMATIC POLYAMIDE MOLDING AND PROCESS FOR PRODUCING THE SAME |
US5525711A (en) * | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
EP2266984A1 (en) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
ES2612472T3 (en) * | 2010-08-31 | 2017-05-17 | Hanmi Science Co., Ltd. | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells |
EP2748169A4 (en) | 2011-09-30 | 2015-06-17 | Kineta Inc | Anti-viral compounds |
KR20140103972A (en) * | 2011-12-22 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | 2,4-diamine-pyrimidine derivatives as serine/threonine kinase inhibitors |
MX2018006781A (en) | 2015-12-03 | 2018-11-09 | Agios Pharmaceuticals Inc | Mat2a inhibitors for treating mtap null cancer. |
CA3034705C (en) | 2016-08-31 | 2021-08-03 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
HUE056777T2 (en) | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
WO2018221433A1 (en) | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | Heteroaryl amine derivative |
JP7150823B2 (en) * | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | Inhibitors of KRas G12C and methods of using same |
PL3774805T3 (en) | 2018-03-30 | 2024-05-06 | Les Laboratoires Servier | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
US11376256B2 (en) | 2018-07-19 | 2022-07-05 | Agency For Science, Technology And Research | Method of treating a methionine-dependent cancer |
AU2019388998A1 (en) | 2018-11-29 | 2021-06-03 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
BR112021012599A2 (en) | 2018-12-27 | 2021-09-08 | Les Laboratoires Servier Sas | AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR TREATMENT OF CANCER |
BR112021012595A2 (en) | 2018-12-27 | 2021-09-08 | Les Laboratoires Servier Sas | AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR TREATMENT OF CANCER |
-
2019
- 2019-12-09 SG SG11202105469YA patent/SG11202105469YA/en unknown
- 2019-12-09 EP EP19832505.2A patent/EP3894396A1/en active Pending
- 2019-12-09 CA CA3121236A patent/CA3121236A1/en active Pending
- 2019-12-09 WO PCT/US2019/065260 patent/WO2020123395A1/en active Application Filing
- 2019-12-09 AU AU2019395338A patent/AU2019395338A1/en active Pending
- 2019-12-09 KR KR1020217021424A patent/KR20210103498A/en unknown
- 2019-12-09 US US17/311,873 patent/US20220106276A1/en active Pending
- 2019-12-09 JP JP2021532487A patent/JP2022512156A/en active Pending
- 2019-12-09 BR BR112021010842-4A patent/BR112021010842A2/en unknown
- 2019-12-09 MX MX2021006841A patent/MX2021006841A/en unknown
- 2019-12-09 CN CN201980081299.9A patent/CN113166078A/en active Pending
- 2019-12-09 MA MA054452A patent/MA54452A/en unknown
- 2019-12-10 TW TW108145188A patent/TW202039487A/en unknown
-
2021
- 2021-02-12 US US17/175,578 patent/US11046691B1/en active Active
- 2021-02-12 US US17/175,581 patent/US11130759B1/en active Active
- 2021-02-12 US US17/175,579 patent/US11084798B1/en active Active
- 2021-05-31 PH PH12021551274A patent/PH12021551274A1/en unknown
- 2021-06-06 IL IL283743A patent/IL283743A/en unknown
- 2021-06-09 CL CL2021001508A patent/CL2021001508A1/en unknown
- 2021-07-06 CO CONC2021/0008895A patent/CO2021008895A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA54452A (en) | 2022-03-16 |
PH12021551274A1 (en) | 2021-12-06 |
CL2021001508A1 (en) | 2022-01-21 |
US11046691B1 (en) | 2021-06-29 |
KR20210103498A (en) | 2021-08-23 |
CA3121236A1 (en) | 2020-06-18 |
BR112021010842A2 (en) | 2021-08-24 |
CO2021008895A2 (en) | 2021-07-30 |
IL283743A (en) | 2021-07-29 |
US20220106276A1 (en) | 2022-04-07 |
CN113166078A (en) | 2021-07-23 |
MX2021006841A (en) | 2021-07-02 |
WO2020123395A1 (en) | 2020-06-18 |
EP3894396A1 (en) | 2021-10-20 |
JP2022512156A (en) | 2022-02-02 |
US11130759B1 (en) | 2021-09-28 |
TW202039487A (en) | 2020-11-01 |
US11084798B1 (en) | 2021-08-10 |
AU2019395338A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283743A (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
IL277455A (en) | Aminopyrimidine derivatives as ctps1 inhibitors | |
IL282386A (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
ZA202204675B (en) | New methylquinazolinone derivatives | |
IL283990A (en) | Substituted oxopyridine derivatives | |
IL279453B (en) | Pyrazole derivatives as malt1 inhibitors | |
IL289197A (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
IL276592A (en) | Derivatives of sobetirome | |
IL279452B (en) | Pyrazole derivatives as malt1 inhibitors | |
IL279938A (en) | Spirochromane derivatives | |
IL290815A (en) | Alpha-d-galactopyranoside derivatives | |
SI3796975T1 (en) | Sulfonylaminobenzamide derivatives | |
HK1252767A1 (en) | Pyrazol-pyridine derivatives as eaat3 inhibitors | |
EP3526216C0 (en) | Benzothiazole derivatives as dyrk1 inhibitors | |
HUE062256T2 (en) | Dihydrochromene derivatives | |
EP3618837A4 (en) | Multitargeted nucleoside derivatives | |
HUE054792T2 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
IL304189A (en) | Pyrazoleamide derivatives | |
GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
GB201806948D0 (en) | Derivatives |